ClinicalTrials.gg
Not yet recruitingNCT07297121Updated Dec 22, 2025

Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece.

An observational study in MCI, Dementia and Mild Cognitive Impairment (MCI), sponsored by Aristotle University Of Thessaloniki. Not yet recruiting at 1 site in Greece. Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Aristotle University Of Thessaloniki · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Dementia with a site in Greece — 6 open to participants now, 6 under way, 2 of them phase 3. Dementia · Greece.

Started
2026
with 1 other
Observational
8 of 15
3 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Aristotle University Of Thessaloniki

Among the 15 studies in Dementia with a site in Greece, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 15th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 15 studies in Dementia with a site in Greece are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Dementia with a site in Greece, or all of them as a file.
02

Study summary

Objective: The purpose of this study is to assess the psychometric qualities of the Montreal Cognitive Assessment (MoCA) version 8.x in Greek, including the MoCA-MIS. We intend to examine the tool's reliability (internal consistency, test-retest reliability) and validity (construct validity, concurrent validity, and known-group validity).

Aim: The findings will support the tool's application for early cognitive impairment identification in clinical and research settings.

Read the detailed description

MoCA is an increasingly common instrument used for cognitive assessment globally. Version 8.x has been translated into Greek, however a validation is of great importance. The participants of this study will be recruited from the outpatient clinic of the 3rd Department of Psychiatry School of Medicine, General University Hospital of Thessaloniki "AHEPA".

The Greek version of MoCA 8.x will be used to evaluate the participants with an analogous cognitive test, such as Addenbrooke's Cognitive Examination (ACE-III) and the M-ACE.

Within 4 weeks, the MoCA will be administered again to a subgroup again in order to evaluate the tool's test-retest reliability. In addition to internal consistency, construct validity (as measured by factor analysis), concurrent validity (correlation with existing tools), and known-group validity (comparing scores between cognitively healthy individuals and those with MCI or dementia), known-group validity will also be evaluated.

Study Type and Time Frames:

Observational Model: Cohort Cross-sectional with a short-timed phase (test-retest). The study is estimated to be completed withing a year's period.

Measure Time Frame Description Internal Consistency Baseline Assessment of internal reliability Test-retest Reliability 4 weeks post-baseline Stability of the test over time Construct Validity Baseline Factor analysis to explore the underlying structure Concurrent Validity Baseline Correlation with established cognitive tools Known-groups Validity Baseline Score comparison across diagnostic groups

Eligibility Criteria:

  • Participants between the ages of 55-85
  • Fluent in Greek to avoid misunderstandings during the assessment
  • Participants must be able to provide informed consent

Exclusion Criteria:

  • History of severe psychiatric or neurological disorders apart from MCI/dementia
  • Patients having acute medical illnesses
  • Patients having severe hearing and/or visual impairments

Study's Population Size:

  • 50-100 Cognitively Healthy Adults
  • 50-75 MCI Patients
  • 50-75 Demented Patients

Location:

Outpatient clinic of the 3rd Department of Psychiatry, School of Medicine, General University Hospital of Thessaloniki "AHEPA", Aristotle University of Thessaloniki, Greece.

Kiriakidi 1, Thessaloniki 546 36 Contact: +302313303110

Principal Investigator:

Dr. Nikitas Arnaoutoglou, MD, PhD Affiliation: Assistant Professor of Psychiatry, 3rd Department of Psychiatry, School of Medicine, General University Hospital of Thessaloniki "AHEPA", Aristotle University of Thessaloniki.

03

Conditions studied

  • MCI
  • Dementia
  • Mild Cognitive Impairment (MCI)

Keywords

  • MCI
  • MoCA
  • MoCA-MIS
  • Validation
  • Mild Cognitive Impairment
  • screening
  • dementia
  • memory testing
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • 50-100 Cognitively Healthy Adults
  • 50-75 MCI Patients
  • 50-75 Demented Patients

The participants of this study will be recruited from the outpatient clinic of the 3rd Department of Psychiatry School of Medicine, General University Hospital of Thessaloniki "AHEPA".

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants between the ages of 55-85
  • Fluent in Greek to avoid misunderstandings during the assessment
  • Participants must be able to provide

Exclusion criteria

Exclusion Criteria:

  • History of severe psychiatric or neurological disorders apart from MCI/dementia
  • Patients having acute medical illnesses
  • Patients having severe hearing and/or visual impairments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Target follow-up
4 Weeks
Patient registry
Yes

Groups and cohorts

  • Control Group
  • Group were patients have a MCI diagnosis
  • Demented patients
06

What researchers measure

Primary outcomes

  1. The Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece.

    Time frame: From enrollment to the end of the follow-up period at 4 weeks.

07

Study locations

1 site
  • Outpatient clinic of the 3rd Department of Psychiatry, School of Medicine, General University Hospital of Thessaloniki "AHEPA", Aristotle University of Thessaloniki, Greece.
    Thessaloniki, 54636, Greece
    • Dr. Nikitas A. Arnaoutoglou, MD, PhD · Contactnarnaou@auth.gr · 302313303110
08

References and documents

Publications

  • Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke's Cognitive Examination III in frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord. 2013;36(3-4):242-50. doi: 10.1159/000351671. Epub 2013 Aug 15. PubMed 23949210 ↗
  • Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry. 2019 Feb;34(2):233-242. doi: 10.1002/gps.5016. Epub 2018 Nov 27. PubMed 30370616 ↗
  • Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. J Am Geriatr Soc. 2014 Apr;62(4):679-84. doi: 10.1111/jgs.12742. Epub 2014 Mar 17. PubMed 24635004 ↗
  • Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. PubMed 15817019 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jun 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297121
Collaborators
MoCA Clinic and Institute
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Dr Nikitas A. Arnaoutoglou, MD, PhD
Contact
narnaou@auth.gr
+302313303110

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion